ClinicalTrials.gg
RecruitingNCT05160480Updated Oct 27, 2026

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

An observational study in Prostate Cancer, Breast Cancer and Neuroendocrine Tumors, sponsored by University of California, Davis. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of California, Davis · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 27, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
9
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Prostatic Neoplasms by University of California, Davis — 5 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · University of California, Davis.

Started
2024
with 1 other
Observational
3 of 19
1 open now
Registered
14th of 19
by date

Among the 19 studies in Prostatic Neoplasms by University of California, Davis, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 19 studies in Prostatic Neoplasms by University of California, Davis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Prostatic Neoplasms by University of California, Davis, or all of them as a file.
02

Study summary

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

03

Conditions studied

  • Prostate Cancer
  • Breast Cancer
  • Neuroendocrine Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited by physicians, primary care physicians, radiologists, and research team members who will identify potential participants and notify a research team member to assist with consenting. The research team will also screen potential patients from the oncology clinical schedules. When a potential participant is identified, a member of the research team will contact the referring physician and/or a clinical team member in charge of the patient's care and request permission to contact the patient. If the referring physician/clinical team agrees, a member of the research team will contact the patient.

Eligibility criteria

18F-PSMA (n=3) and 68Ga-PSMA (n=3)

Inclusion criteria:

  • Persons >18 yo with suspected prostate cancer
  • Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.

    68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)

Inclusion Criteria:

  • Persons > 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
  • Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.

Exclusion Criteria:

  • Recent administration of long-acting somatostatin analogs

Exclusion Criteria for all participants:

  • Adults unable to consent
  • Pregnant/lactating persons
  • Prisoners
  • Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
  • Uncontrolled claustrophobia
  • Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
9 participants (estimated)
Patient registry
No

Groups and cohorts

  • Total-body PET scan

    All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.

    Diagnostic Test: Total-body PET imaging

Interventions

  • Diagnostic testTotal-body PET imaging

    Total-body PET imaging at different timepoints

06

What researchers measure

Primary outcomes

  1. measure radiotracer avidity

    measure radiotracer avidity, i.e. standardized uptake value measurements (SUV max and mean) of tumor and normal tissue as a function of time with 18F-PSMA, 18F-FES, 68Ga DOTATATE in a total-body PET scanner among men with suspected prostate cancer metastasis, patients suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors, and patients with recurrent or metastatic breast cancer.

    Time frame: One study imaging visit lasting up to 10 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2027, 38 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 38 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Dec 16, 2021
StartActual
Jun 7, 2024
Primary completionEst.
Sep 1, 2027was Sep 2026
CompletionEst.
Sep 1, 2027was Sep 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Recruiting
changed Oct 27, 2026
Sites
UC Davis EXPLORER Molecular Imaging Center is now Recruiting
Oct 27, 2026
Primary completion
Sep 1, 2026→Sep 1, 2027
Oct 27, 2026
Study completion
Sep 1, 2026→Sep 1, 2027
Oct 27, 2026
Contact
Study contact now listed: added r•••@health.ucdavis.edu · •••9004. See the current contact
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • UC Davis EXPLORER Molecular Imaging Center · Sacramento, United StatesContact added d•••@ucdavis.edu · •••7749
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Enrolling by invitation→Recruiting
    UC Davis EXPLORER Molecular Imaging Center is now Recruiting
    Primary completion Sep 1, 2026→Sep 1, 2027
    Study completion Sep 1, 2026→Sep 1, 2027
    Contact Study contact now listed: added r•••@health.ucdavis.edu · •••9004. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • UC Davis EXPLORER Molecular Imaging Center · Sacramento, United StatesContact added d•••@ucdavis.edu · •••7749
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05160480
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Jun 7, 2024
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Clinical Research Team
Contact
research-radiology-som@health.ucdavis.edu
916-731-9004
Lorenzo Nardo, MD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion